Paratek Pharmaceuticals
Specialty pharmaceutical company focused on development, regulatory approval, commercialization, and lifecycle management of therapies for infectious diseases and targeted therapeutic areas. Activities include clinical and non-clinical development, medical affairs and scientific communications, pharmacovigilance, government biodefense programs and contracting, manufacturing onshoring and supply security, and commercialization partnerships.
Industries
Nr. of Employees
large (251-1000)
Paratek Pharmaceuticals
Patents
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10835542-B2
View Details9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10383884-B2
View Details
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10835542-B2
View Details9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10383884-B2
View DetailsProducts
Omadacycline (once-daily oral and intravenous antibiotic)
Once-daily oral and intravenous antibiotic indicated for adult community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; developed to address tetracycline resistance and studied for additional indications, including biodefense.
Intranasal corticosteroid topical delivery (exhalation-based system)
Prescription intranasal topical corticosteroid delivered using an exhalation-based delivery system designed to target deeper regions of the nasal cavity for chronic rhinosinusitis.
Sarecycline (oral antibiotic marketed by partner)
Oral tetracycline-class antibiotic indicated for inflammatory lesions of non-nodular moderate to severe acne; marketed in the U.S. by a commercial partner.
Omadacycline (once-daily oral and intravenous antibiotic)
Once-daily oral and intravenous antibiotic indicated for adult community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; developed to address tetracycline resistance and studied for additional indications, including biodefense.
Intranasal corticosteroid topical delivery (exhalation-based system)
Prescription intranasal topical corticosteroid delivered using an exhalation-based delivery system designed to target deeper regions of the nasal cavity for chronic rhinosinusitis.
Sarecycline (oral antibiotic marketed by partner)
Oral tetracycline-class antibiotic indicated for inflammatory lesions of non-nodular moderate to severe acne; marketed in the U.S. by a commercial partner.
Services
Provision of medical information to U.S. healthcare professionals, management of publications and presentations, disease and product education resources, and field medical support.
Review and funding of investigator-initiated research proposals and educational grants to support clinical and preclinical scientific studies and independent medical education.
Engagement and negotiation for regional licensing, collaborations, and commercial partnerships; integration of acquired assets into a multi-product commercial platform.
Program management and execution for government contracts supporting development, onshoring, manufacturing security, and procurement of medical countermeasures.
Provision of standardized research materials for non-clinical microbiology studies and routine laboratory testing on request.
Access to antimicrobial surveillance datasets and informational resources on reference laboratory services and AST device compatibility to support clinical and laboratory decision-making.
Provision of medical information to U.S. healthcare professionals, management of publications and presentations, disease and product education resources, and field medical support.
Review and funding of investigator-initiated research proposals and educational grants to support clinical and preclinical scientific studies and independent medical education.
Engagement and negotiation for regional licensing, collaborations, and commercial partnerships; integration of acquired assets into a multi-product commercial platform.
Program management and execution for government contracts supporting development, onshoring, manufacturing security, and procurement of medical countermeasures.
Provision of standardized research materials for non-clinical microbiology studies and routine laboratory testing on request.
Access to antimicrobial surveillance datasets and informational resources on reference laboratory services and AST device compatibility to support clinical and laboratory decision-making.
Expertise Areas
- Clinical trial management for infectious diseases
- Antibacterial drug development and microbiology surveillance
- Biodefense medical countermeasure development under Animal Rule
- Regulatory strategy and post-marketing compliance
Key Technologies
- Oral and intravenous formulation development
- Topical intranasal delivery via exhalation-based systems
- Preclinical inhalational models in rabbit and non-human primate
- In vitro MIC testing and antimicrobial susceptibility panels
News & Updates
Poster and oral presentations reporting clinical and non-clinical data, including in vitro surveillance and clinical study results.
Presentations included integrated safety analyses from Phase 3 trials and a blinded randomized pivotal animal efficacy study supporting pulmonary anthrax development under Animal Rule.
Top-line positive results from rabbit and non-human primate therapeutic efficacy studies supporting continued procurement under a federal biodefense contract.
Completed a combination with another specialty company to expand a multi-product commercial platform and diversify therapeutic areas.
Multicenter real-world evaluation of antibiotic use for multi-drug resistant infections presented at IDWeek 2022.
Preclinical study evaluating antibiotic potential against A. baumannii and K. pneumoniae in combat wound models, presented at MHSRS 2022.
Poster and oral presentations reporting clinical and non-clinical data, including in vitro surveillance and clinical study results.
Presentations included integrated safety analyses from Phase 3 trials and a blinded randomized pivotal animal efficacy study supporting pulmonary anthrax development under Animal Rule.
Top-line positive results from rabbit and non-human primate therapeutic efficacy studies supporting continued procurement under a federal biodefense contract.
Completed a combination with another specialty company to expand a multi-product commercial platform and diversify therapeutic areas.
Multicenter real-world evaluation of antibiotic use for multi-drug resistant infections presented at IDWeek 2022.
Preclinical study evaluating antibiotic potential against A. baumannii and K. pneumoniae in combat wound models, presented at MHSRS 2022.